Alnylam Pharmaceuticalsvs.United Therapeutics
ALNY vs UTHR · both in Biotech & innovation, part of the Medicine, pharma & life science value chain: Innovation-driven biotech companies focused on novel treatment modalities.
Alnylam Pharmaceuticals is about 1.4× larger than United Therapeutics by market cap; United Therapeutics trades at the lower P/E (17.0 vs 37.6); year to date, United Therapeutics leads (+5.3% vs −40.6%).
Side by side
| ALNY | UTHR | |
|---|---|---|
| Market cap | $30.4B | $22.3B |
| Price | $240.08 | $518.53 |
| Today | +1.7% | +1.1% |
| Return YTD | −40.6% | +5.3% |
| Return 1Y | −48.1% | +64.3% |
| P/E | 37.6 | 17.0 |
| P/S | 6.3 | 7.1 |
| P/B | 22.4 | 3.5 |
Data as of 2026-08-26 · updates daily after U.S. close
The two companies
Alnylam PharmaceuticalsALNY
Turns RNA interference into drugs, mostly for rare and cardiovascular disease.
Full ALNY profile →United TherapeuticsUTHR
Pulmonary hypertension accounts for the marketed drugs, Tyvaso, Remodulin and Orenitram among them. A separate programme works on organs for transplant, including xenotransplantation.
Full UTHR profile →More ALNY & UTHR comparisons
Other head-to-heads in the Biotech & innovation segment.